within Pharmacolibrary.Drugs.ATC.N;

model N05AB10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.01,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AB10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Perazine is a typical antipsychotic drug of the phenothiazine class, used primarily for the treatment of schizophrenia and other psychoses. It was widely used in Europe but is now rarely prescribed, as it has largely been replaced by newer antipsychotics. It is not widely approved or used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies with parameter values are available for perazine. The following pharmacokinetic parameters are estimated based on average values reported for phenothiazine antipsychotics in adults following oral administration.</p><h4>References</h4><ol><li><p>Breyer-Pfaff, U, et al., &amp; Straube, E (1983). Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data. <i>Pharmacopsychiatria</i> 16(5) 160–165. DOI:<a href=&quot;https://doi.org/10.1055/s-2007-1019491&quot;>10.1055/s-2007-1019491</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6140695/&quot;>https://pubmed.ncbi.nlm.nih.gov/6140695</a></p></li><li><p>Awata, N, et al., &amp; Kawashima, T (1995). [Metabolism of lomerizine hydrochloride (KB-2796) in rats]. <i>Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</i> 115(2) 120–129. DOI:<a href=&quot;https://doi.org/10.1248/yakushi1947.115.2_120&quot;>10.1248/yakushi1947.115.2_120</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7722879/&quot;>https://pubmed.ncbi.nlm.nih.gov/7722879</a></p></li><li><p>Gaebel, W, et al., &amp; Schley, J (1992). Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia. <i>Progress in neuro-psychopharmacology &amp; biological psychiatry</i> 16(6) 891–900. DOI:<a href=&quot;https://doi.org/10.1016/0278-5846(92)90107-p&quot;>10.1016/0278-5846(92)90107-p</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1355303/&quot;>https://pubmed.ncbi.nlm.nih.gov/1355303</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AB10;
